Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 4/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17828147 | 0.96 | USP30 (0.42) | GAAPIM1PIM2PIK3C3ATM | |
| SCHEMBL17820218 | 0.95 | PIK3C3 (0.40) | GAAPIM1PIM2PIK3C3ATM | |
| SCHEMBL17828148 | 0.94 | PIK3C3 (0.42) | GAAPIM1PIM2PIK3C3ATM | |
| SCHEMBL17828149 | 0.92 | PIK3C3 (0.42) | PIM1PIM2PIK3C3ATMUSP30 | |
| SCHEMBL17820553 | 0.90 | PIK3C3 (0.40) | GAAPIK3C3ATMBTK | |
| SCHEMBL17820420 | 0.88 | GAA (0.41) | GAAPIM1PIM2PIK3C3ATM | |
| SCHEMBL17828158 | 0.86 | PIK3C3 (0.40) | GAAPIK3C3ATMUSP30TGFBR1 | |
| SCHEMBL17821119 | 0.86 | PIK3C3 (0.43) | GAAPIK3C3ATM | |
| SCHEMBL17820146 | 0.86 | PIK3C3 (0.40) | GAAPIK3C3ATMBTK | |
| SCHEMBL17820263 | 0.86 | PIK3C3 (0.41) | GAAPIK3C3ATMBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | GAA 4389/4885PIM1 3053/4885PIM2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.